Clinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2

The American Journal of Pediatric Hematology/oncology
M H FreedmanE W Gelfand

Abstract

The properties of the recombinant DNA-derived human leukocyte interferon, HuIFN alpha 2, were studied in patients with advanced leukemia or lymphoma. In vitro, HuIFN alpha 2 induced an increased activity of 2-5A synthetase in leukemic and in control cells indicating cellular responsiveness to IFN. HuIFN alpha 2 also produced a dose-responsive decline in marrow leukemia blast progenitor colony growth, and in normal hematopoietic colony formation in vitro, confirming its antiproliferative effect. A course of intravenous therapy given to a lymphoma patient produced a modest decline in peripheral white blood cell (WBC) and neutrophil counts; higher, more frequent doses in a second patient induced a profound drop in WBC's, neutrophils, and platelets. When the leukemia patients were given an intravenous course of HuIFN alpha 2 as a sole agent, blast cytoreduction was seen in peripheral blood in three patients, and in marrow of one patient with acute myeloblastic leukemia (AML). Elevated 2-5A synthetase levels could be detected after therapy. No modulation of leukemic cell markers was seen after in vitro or in vivo treatment with HuIFN alpha 2, implying that the cytoreduction was not linked to blast cell differentiation. These studies...Continue Reading

Citations

Jun 12, 1998·Pharmacology & Therapeutics·M R Player, P F Torrence
Jan 29, 2011·Leukemia·S AnguilleE L J M Smits
Oct 1, 1991·British Journal of Haematology·H MellstedtG Juliusson
Oct 1, 1996·Zentralblatt für Veterinärmedizin. Reihe A·P SartorelliT Baglioni
Apr 1, 1988·Hematological Oncology·H Mellstedt
Aug 1, 1991·Zentralblatt für Veterinärmedizin. Reihe B. Journal of veterinary medicine. Series B·M TråvénB Larsson
Jan 1, 1990·European Journal of Haematology. Supplementum·P MazzaP G Gobbi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.